Sufentanil, sold under the brand names of Dsuvia and Sufenta, is basically a synthetic opioid analgesic drug, which is used for the medication of acute pain relief. It helps to offer properties of sedation and this makes it a good analgesic component of anesthetic regimen during a surgical process.

Download the sample report at: https://www.pharmaproff.com/request-sample/1167

It has greater potency than morphine and Fentanyl, often used in surgery and post-operative pain management for patients that are heavily opioid dependent or tolerant because of long term opiate use for chronic pain or illicit opiate use. In the present market, Sufentanil has proven to be the strongest opioid painkiller available. 


In 2018, the Food and Drug Association had approved Dsuvia, a sublingual tablet form of the drug, that was developed in a collaboration between AcelRx Pharmaceuticals Inc. and the United States Department of Defense for use in battlefield settings where intravenous treatments may not be available. Some of the side-effects include heart rhythm irregularity, blood pressure changes and nausea/vomiting.


This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM).


















Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.

Request to get the sample report at: https://www.pharmaproff.com/request-sample/1117

The only efficient treatment for pontine glioma is radiotherapy; as surgery is not possible due to the tumor’s position in the brain stem. Company like Y-mAbs Therapeutics Inc. is in the process of developing omburtamab for the treatment of pontine glioma.